Filing Flows › Praxis Precision Medicines (PRAX) › Q4 2024
Praxis Precision Medicines (PRAX) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Feb 28, 2025
Praxis Precision Medicines (PRAX) reported revenue of $7.5M for the fourth quarter 2024 (Q4 2024), up 14-fold from a year earlier and up 25-fold from the quarter before. Operating margin was -857.0%, net loss $58.7M (786.3% of revenue).
Praxis Precision Medicines, Q4 2024: revenue $7.5M (14× year over year), operating margin -857.0%, net loss $58.7M, operating cash flow −$56.1M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.5M | 25× | 14× |
| Operating profit | −$64.0M | — | — |
| Net earnings | −$58.7M | — | — |
| Operating cash flow | −$56.1M | — | — |
What changed
Revenue was $7.5M in Q4 2024, up 1349% year over year and up 2371% from the previous quarter.
Operating costs exceeded revenue by $64.0M, an operating margin of -857.0%. Total costs grew 152% against revenue growth of 1349%. The fastest-growing cost line was Research & development (+206%). The quarter ended with a net loss of $58.7M, wider than the previous quarter's $51.9M loss.
Operating cash flow was −$56.1M. Non-cash charges added back $47K of depreciation and $8.6M of share-based compensation. Working capital and other items used $6.1M.
Questions
What was Praxis Precision Medicines' revenue in the fourth quarter 2024?
Praxis Precision Medicines (PRAX) reported revenue of $7.5M for the fourth quarter 2024 (Q4 2024), up 14-fold from a year earlier and up 25-fold from the quarter before.
Was Praxis Precision Medicines profitable in the fourth quarter 2024?
Operating loss was $64.0M (-857.0% of revenue) and net loss $58.7M.